Q3 2021 is out and looks great Higher sales and growingI wish the did better PR but the financials look very strong and the company is definitely a winner with Polytope
https://www.businesswire.com/news/home/20210317005871/en/ImmunoPrecise-Reports-Financial-Results-and-Recent-Business-Highlights-for-Third-Quarter-of-2021-Fiscal-Year
- Increased revenue for the nine months ended January 31st, 2021 by 32% to $13,035,522.
- Record adjusted EBITDA for the nine months ended January 31st, 2021 of $2,564,257, a significant increase from the $18,356 for the nine months ended January 31, 2020.
- Closed USD$21.7 million bought deal offering of common shares.
- Closed over-allotment option associated with the previously completed bought deal of USD$3.3 Million
- ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease
- ImmunoPrecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation
- Commenced trading on Nasdaq stock exchange
- Announced positive data from pre-clinical study of TATX-03 Polytope™ monoclonal antibody cocktail candidate against COVID-19